Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.92 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | DGKA | P23743 | 1/20 | 0.53 |
| ▸ | PRKCA | P17252 | 3/20 | 0.53 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL317355 | 0.96 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| Isopropyl Palmitate SCHEMBL1133116 | 0.96 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL1278398 | 0.96 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL126208 | 0.96 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| Isopropyl Palmitate SCHEMBL22578002 | 0.96 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL1173030 | 0.96 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| Isopropyl Palmitate SCHEMBL7743 | 0.96 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL43528 | 0.96 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL29523 | 0.96 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL13044433 | 0.96 | LMNA (1.00) | LMNAMAPTMAPK1ALDH1A1DGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11992481-B2 | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-05-28 | — | — | US | disclosed |
| US-20220249456-A1 | USE OF 2-SUBSTITUTED INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-08-11 | — | — | US | disclosed |
| CN-109152771-B | Use of 2-substituted indazoles for the treatment and prevention of autoimmune diseases | 拜耳医药股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| US-20210085664-A1 | USE OF 2-SUBSTITUTED INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-25 | — | — | US | disclosed |
| US-20190125736-A1 | USE OF 2-SUBSTITUTED INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-02 | — | — | US | disclosed |
| CN-109152771-A | The indazole that 2- replaces is used to treat and prevent the purposes of autoimmune disease | 拜耳医药股份有限公司 | 2019-01-04 | — | — | CN | disclosed |
| US-6610675-B1 | Identifying nontoxic therapeutically inactive metabolite of drug which elicits particular therapeutic response, converting inactive metabolite into activated structurally related drug species which cleaves in vivo to inactive metabolite | Bodor, Nicholas S. | 2003-08-26 | — | — | US | disclosed |
| US-4996335-A | Soft steroids having anti-inflammatory activity | Bodor, Nicholas S. (US) | 1991-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125736-A1 | USE OF 2-SUBSTITUTED INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES | IDO2, IL33, IDO1 | LMNA 4672/4885MAPT 1611/4885MAPK1 3569/4885 |
| US-20210085664-A1 | USE OF 2-SUBSTITUTED INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES | IDO2, IL33, IDO1 | LMNA 4672/4885MAPT 1611/4885MAPK1 3569/4885 |
| US-20220249456-A1 | USE OF 2-SUBSTITUTED INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES | IDO2, IL33, IDO1 | LMNA 4672/4885MAPT 1611/4885MAPK1 3569/4885 |
| US-11992481-B2 | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases | IDO2, IL33, IDO1 | LMNA 4672/4885MAPT 1611/4885MAPK1 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.